Novel Technology Could Transform Production Of Flu Vaccine With Enhanced Potency, Manufacturing Capacity And Cost-Effectiveness
August 27th, 2008 by 
admin VaxInnate Corporation declared that its M2e coupler contagion immunogen politician was innocuous and immunogenic in its prototypal Phase I clinical trial, upbringing hopes for a coupler contagion immunogen that could wage endorsement against seasonal and pandemic contagion strains.
Posted in Immunology | 